Intel stock spikes after report of possible US government stake
PDS Biotechnology (NASDAQ:PDSB) Corporation’s stock (PDSB) has reached a 52-week low, dipping to $1.12, marking a steep decline from its 52-week high of $4.42. With a current market capitalization of $42.5 million and an EBITDA of -$36.3 million for the last twelve months, investors navigate a tumultuous market environment. The biopharmaceutical company, which focuses on developing immunotherapies for cancer and infectious diseases, has seen its shares significantly retreat from higher levels over the past year. This downturn reflects a broader trend for the company, with PDSB stock experiencing a stark 1-year decline of 70.4%. According to InvestingPro analysis, which provides 8 additional key insights about PDSB, the company’s financial health score is currently rated as WEAK, with analysts setting price targets ranging from $4.50 to $13.00. The decline underscores the volatility and challenges faced by biotech firms, which are often subject to intense market scrutiny and regulatory pressures. Investors are closely monitoring the company’s pipeline developments and strategic initiatives for signs of a potential rebound or further headwinds.
In other recent news, PDS Biotechnology Corp reported its financial results for the fourth quarter and full year of 2024, showing a narrowed net loss of $37.6 million, an improvement from the $42.9 million loss in 2023. The company’s earnings per share (EPS) for the fourth quarter was ($0.21) and ($1.03) for the full year, both surpassing initial and consensus estimates. Despite the improved financial performance, PDS Biotechnology acknowledged the need to seek additional funding to support ongoing operations, including the completion of the VERSATILE-003 trial. The company successfully raised $11 million through a direct offering in February 2025, contributing to its cash reserves of $41.7 million at the end of 2024.
Analyst firm H.C. Wainwright revised the price target for PDS Biotechnology’s stock from $21.00 to $13.00, maintaining a Buy rating, reflecting confidence in the company’s potential despite the target adjustment. PDS Biotechnology announced the initiation of the Phase 3 VERSATILE-003 study and received FDA clearance for an Investigational New Drug application to study a combination therapy for advanced colorectal carcinoma. Additionally, results from the Phase 2 IMMUNOCERV trial were presented at a major conference, showcasing the company’s progress in clinical trials. The company is optimistic about its future, with plans to continue enrolling patients in its trials and exploring strategic partnerships and non-dilutive funding options.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.